Sign In

Alice Zhang

Chief Executive Officer at Verge Genomics

Alice Zhang is a highly accomplished professional with a diverse educational background and strong leadership experience.

She completed her MD/PhD in Neuroscience at the prestigious David Geffen School of Medicine at UCLA, demonstrating her commitment to advancing medical and scientific knowledge.

Prior to this, Alice excelled at Princeton University, where she earned an A.B. in Molecular Biology with high honors, further solidifying her expertise in the field.

Her academic journey began at Thomas Jefferson High School for Science and Technology, where she likely laid the foundation for her successful career in the sciences.

Alice Zhang has held key roles in notable organizations, including serving on the Board of Directors at the California Life Sciences Association (CLSA), where she contributed to the growth and development of the life sciences industry.

She also co-founded Verge Genomics and served as its CEO, showcasing her entrepreneurial spirit and ability to drive innovation in the biotech sector.

With a background in both academia and business, Alice brings a unique perspective to the intersection of science, medicine, and industry.

Her experiences as an MD/PhD candidate, coupled with her leadership positions, reflect a dedication to making significant contributions to the field of life sciences.

Highlights

Apr 21 · linkedin

In 2022, 25 female biotech CEOs got together and asked: how can we redefine what it means to support other women? This weekend, I spent my third year with now over 60 (!) female CEOs shaping biotech and I realized: these women have changed my life. This is what the future of leadership looks like👇#BiotechCEOSisterhood

Feb 7 · linkedin

This important paper was published today in Cell with some quite compelling data further validating PIKfyve as a promising therapeutic target in ALS and uncovering its mechanism. We identified this target from the CONVERGE platform a number of years ago, and are happy to see independent validation showing that PIKFYVE inhibition reduces motor impairment and extends survival in multiple animal models of ALS as well as patient-derived motor neurons across many diverse forms of ALS including sporadic, C9ORF72, TDP43, and FUS.

We agree that there is a pressing need for therapies that rescue multiple forms of ALS given that genetic therapies do not address the majority of patients who are sporadic. This is why at Verge Genomics we are excited to be developing the leading PIKFYVE small molecule inhibitor and the only one specifically optimized for CNS diseases in clinical development.

Alice Zhang
Add to my network

Location

San Francisco, California, United States